Kandi Zhang | Medicine and Dentistry | Best Researcher Award

Dr. Kandi Zhang | Medicine and Dentistry | Best Researcher Award

Doctor from Department of Cardiology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, China

Dr. Kandi Zhang is an emerging medical researcher and clinician specializing in internal medicine with a primary focus on cardiology. Born in September 1993, she is currently affiliated with the Department of Cardiology at Shanghai Ninth People’s Hospital, which is part of Shanghai Jiao Tong University School of Medicine, one of China’s most prestigious institutions. Her clinical and research work reflects a strong dedication to advancing diagnostic and therapeutic methods for cardiovascular diseases, particularly through innovative applications of imaging technologies, antiplatelet therapies, and proteomic biomarker analysis. She has authored several peer-reviewed publications that explore the clinical and molecular aspects of acute coronary syndrome and myocardial infarction. Dr. Zhang’s combination of academic rigor and hands-on clinical expertise has allowed her to contribute meaningful insights to the field. Her collaborations with interdisciplinary teams and consistent publication in high-quality journals suggest a trajectory toward leadership in cardiovascular medicine. With a commitment to both patient-centered care and scientific discovery, she bridges the gap between medical innovation and clinical practice, positioning herself as a key contributor to the future of life sciences research in cardiology.

Professional Profile

Education

Dr. Kandi Zhang holds a Doctorate in Internal Medicine, earned through advanced medical education and research training at the Shanghai Jiao Tong University School of Medicine. This institution is internationally recognized for its rigorous curriculum, cutting-edge medical technology, and high-impact research environment. Her academic background provided her with comprehensive knowledge in physiology, pathology, pharmacology, and advanced clinical methodologies, with a particular concentration in cardiovascular medicine. During her doctoral studies, Dr. Zhang received mentorship from leading cardiologists and participated in clinical rotations and research initiatives at Shanghai Ninth People’s Hospital. The combination of theoretical education and practical exposure enabled her to specialize in both diagnosis and treatment of complex cardiac conditions. Her doctoral research likely involved extensive literature reviews, experimental design, clinical data analysis, and application of medical imaging and laboratory techniques. This educational foundation established her competence in evidence-based medicine, advanced diagnostics, and translational research. Through this training, she cultivated the analytical, technical, and clinical judgment skills required to contribute effectively to medical science. Her continuous engagement in academic publishing indicates that she has maintained a strong scholarly presence beyond her formal education, enriching her academic qualifications with real-world impact.

Professional Experience

Dr. Kandi Zhang’s professional experience is rooted in her role at the Department of Cardiology, Shanghai Ninth People’s Hospital, a highly respected clinical and research institution in China. As a practicing cardiologist and medical researcher, she is actively involved in both patient care and scientific inquiry. Her responsibilities include diagnosing and managing cardiovascular disorders, performing and interpreting diagnostic imaging, and participating in interdisciplinary case consultations. In parallel, she conducts clinical research with a focus on cardiovascular interventions, such as myocardial infarction management without reperfusion, left atrial appendage closure procedures, and the use of proteomic platforms to analyze biomarkers in acute coronary syndrome. Her position allows her to translate bedside observations into research hypotheses, bridging clinical care with data-driven innovation. Additionally, Dr. Zhang collaborates with colleagues across departments and institutions, contributing to multi-author research papers and bringing new insights to existing cardiology practices. Her dual engagement in research and clinical services provides a unique advantage, allowing her to contribute to real-time advancements in treatment protocols. This experience has also enhanced her leadership capabilities in conducting clinical trials, publishing scientific findings, and shaping evidence-based medical practices, making her a valuable contributor to both national and international cardiology communities.

Research Interest

Dr. Kandi Zhang’s research interests lie at the intersection of clinical cardiology, cardiovascular imaging, and molecular biomarker discovery. Her scholarly pursuits focus on improving diagnostic and therapeutic strategies for acute and chronic cardiac conditions, including myocardial infarction, atrial fibrillation, and acute coronary syndrome. She is particularly interested in the pre-treatment efficacy of antiplatelet medications in non-reperfused myocardial infarction cases, a subject with significant implications for emergency cardiac care. Another key area of her research involves comparative studies of imaging modalities for left atrial appendage closure—an essential technique for stroke prevention in atrial fibrillation patients. Her recent work has expanded into proteomics, exploring biomarker signatures in young patients with acute coronary syndrome, which opens possibilities for personalized medicine and early detection strategies. Dr. Zhang is committed to translational research that can swiftly impact clinical decision-making. By integrating data from various sources—including imaging, clinical trials, and molecular assays—her work advances the precision and effectiveness of cardiac interventions. She aspires to contribute to the development of non-invasive, cost-effective, and scalable diagnostics for cardiovascular diseases. Her research interests reflect a broader vision of integrating technology, biology, and clinical medicine to address pressing challenges in heart health globally.

Research Skills

Dr. Kandi Zhang possesses a robust set of research skills that complement her clinical expertise. Her methodological proficiency spans clinical trial design, statistical analysis, medical imaging evaluation, and biomarker identification using proteomics. She is adept at using various imaging techniques to support therapeutic interventions, as evidenced by her publication on evaluating orifice diameters for atrial appendage closure. Her familiarity with experimental protocols, animal models, and in vitro assays—such as her work on myocardial infarction in mice—demonstrates her versatility in both basic and applied research. She also shows skill in bioinformatics and data interpretation, especially in translating proteomic findings into clinically relevant insights. Furthermore, she has strong experience in scholarly writing, data visualization, and peer-reviewed publishing, which are essential for knowledge dissemination and academic contribution. Her ability to work collaboratively on multi-author projects highlights her communication and teamwork skills, crucial for multidisciplinary research environments. Dr. Zhang is also proficient in integrating patient data with clinical outcomes, allowing for a nuanced understanding of treatment efficacy. These research skills enable her to contribute to innovative, evidence-based practices in cardiology, and position her as a strong candidate for collaborative projects across the life sciences and medical research domains.

Awards and Honors

While specific named awards are not explicitly listed in the available profile, Dr. Kandi Zhang’s consistent publication in high-impact, peer-reviewed journals and affiliation with a top medical university suggest academic excellence and institutional recognition. Being a first or lead author in multiple scientific papers published in journals such as Cardiology Journal, Clinical Cardiology, and Frontiers in Cardiovascular Medicine indicates that her work is well-regarded within the cardiology and life sciences communities. Such scholarly visibility often accompanies internal honors such as best researcher accolades, conference recognitions, or research funding awards within the academic medical network. Her role at Shanghai Ninth People’s Hospital—a center for high-level research and patient care—also implies that she has undergone competitive selection processes and met stringent performance standards. Moreover, her early-career contributions, particularly in bridging clinical and molecular research, may position her for future international awards in cardiovascular research and life sciences innovation. If she continues on this trajectory, it is likely that formal recognitions and honors will follow as her influence in the field expands.

Conclusion

Dr. Kandi Zhang exemplifies the qualities of an innovative and impactful researcher in the field of life sciences, particularly in cardiovascular medicine. Through a combination of clinical practice, rigorous academic training, and a solid research portfolio, she has established herself as a credible and forward-thinking contributor to cardiology. Her studies on antiplatelet drug efficacy, imaging modality optimization, and proteomics-based biomarker identification highlight her commitment to solving real-world health challenges through science. While her profile would benefit from broader international exposure and interdisciplinary collaboration, her current achievements mark her as a rising figure in translational cardiovascular research. With continued effort and strategic partnerships, she is well-positioned to lead impactful projects that could redefine patient care standards in cardiology. As she advances in her career, Dr. Zhang has the potential to influence both academic and clinical landscapes, making her a strong candidate for recognition through life sciences innovation awards and future leadership roles in global medical research.

Publications Top Notes

  • Does Spontaneous Echo Contrast in the Left Atrial Appendage Increase Thromboembolism Risk After Left Atrial Appendage Closure? A Retrospective Study on Its Impact on Device‐Related Thrombosis and Arterial Thromboembolic Events

    • Authors: Kandi Zhang, Hanwen Yu, Yihua Lu, Peng Zhang, Dongsheng Liu, Jianpeng Huang, Jing Zhou, Yiqian Yuan, Zongqi Zhang, Qingyong Zhang et al.

    • Year: 2025

  • Clinical Characteristics and Biomarkers Feature Analysis Using a Proteomics Platform in Young Patients with Acute Coronary Syndrome

    • Authors: Zhang K, Wang F, Yu Q, Song Y, Gu J, He Q, Zhang J

    • Year: 2024

  • Angiopoietin-like Protein 2 Inhibits Thrombus Formation

    • Authors: Zhang T, Zhang M, Guo L, Liu D, Zhang K, Bi C, Zhang P, Wang J, Fan Y, He Q et al.

    • Year: 2024

  • Identification of Shared Molecular Mechanisms and Diagnostic Biomarkers Between Heart Failure and Idiopathic Pulmonary Fibrosis

    • Authors: Zhang P, Geng L, Zhang K, Liu D, Wei M, Jiang Z, Lu Y, Zhang T, Chen J, Zhang J

    • Year: 2024

  • AGK Potentiates Arterial Thrombosis by Affecting Talin-1 and αIIbβ3-Mediated Bidirectional Signaling Pathway

    • Authors: Zhang P, Jiang H, Yang M, Bi C, Zhang K, Liu D, Wei M, Jiang Z, Keyu Lv, Fang C et al.

    • Year: 2023

  • Role of GPR56 in Platelet Activation and Arterial Thrombosis

    • Authors: Liu D, Zhang P, Zhang K, Bi C, Li L, Xu Y, Zhang T, Zhang J

    • Year: 2022

  • Comparison of Multiple Imaging Modalities for Measuring Orifice Diameter and Selecting Occluder Size in Patients Undergoing Left Atrial Appendage Closure

    • Authors: Kandi Zhang, Jing Zhou, Tiantian Zhang, Zongqi Zhang, Shanliang Jin, Qing He, Junfeng Zhang

    • Year: 2022

  • Pretreatment with Antiplatelet Drugs Improves the Cardiac Function After Myocardial Infarction Without Reperfusion in a Mouse Model

    • Authors: Zhang K, Yang W, Zhang M, Sun Y, Zhang T, Liu J, Zhang J

    • Year: 2019

  • Paired Immunoglobulin-like Receptor B Regulates Platelet Activation

    • Authors: Fan X, Shi P, Dai J, Lu Y, Chen X, Liu X, Zhang K, Wu X, Sun Y, Wang K et al.

    • Year: 2014

Bo Li | Pharmaceutical Science | Best Researcher Award

Prof. Dr. Bo Li | Pharmaceutical Science | Best Researcher Award

Researcher at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

Dr. Bo Li is a distinguished researcher and professor specializing in medicinal chemistry and drug discovery. He currently serves as a professor and MS supervisor at the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the University of Chinese Academy of Sciences. Dr. Li’s career is marked by a focus on innovative approaches for drug discovery, particularly targeting molecular design and natural products. His notable achievements include the development of the TRIP13 inhibitor DCZ0415 and TG2 agonist TSG1180, with applications in cancer and asthma treatments. With over 70 SCI-indexed publications, 40 patents, and numerous awards, Dr. Li has made significant contributions to his field. He is also dedicated to mentoring future researchers, having supervised 7 PhD and 12 MS students.

Professional Profile

Education

Dr. Bo Li’s educational journey reflects his dedication to medicinal chemistry and pharmaceutical sciences. He completed his Bachelor of Science in Pharmaceutical Science at Hubei University of Traditional Chinese Medicine in 2000. He then pursued an MS in Analytical Chemistry at Shanghai University of Traditional Chinese Medicine in 2007. Dr. Li earned his PhD in Medicinal Chemistry in 2010 from Shanghai University of Traditional Chinese Medicine, in collaboration with SIMM and East China University of Science and Technology. Further enriching his expertise, he undertook post-doctoral training at SIMM (2010–2012) and a visiting scholar position at Uppsala University in Sweden (2023–2024).

Professional Experience

Dr. Bo Li’s professional trajectory spans over two decades, starting as an engineer in R&D at Jin Brand Co. Ltd. from 2000 to 2004. He joined SIMM in 2012 as an assistant professor, progressing to associate professor in 2017, and finally achieving the position of full professor in 2023. Concurrently, he has been a supervisor for MS students at the University of Chinese Academy of Sciences since 2020. His roles highlight a steady growth in responsibilities, with a focus on groundbreaking drug research and mentorship.

Research Interest

Dr. Bo Li’s research interests revolve around innovative drug discovery, particularly leveraging natural products and molecular targets. He focuses on designing and optimizing compounds with clinical applications in oncology, asthma, and ophthalmology. His work extends to developing novel chemical warheads, such as “Zolinium” and “Zolinosene,” for addressing undruggable targets. Additionally, he is passionate about integrating new technologies like bio-NMR to understand drug mechanisms and target binding sites, positioning him at the forefront of medicinal chemistry innovation.

Research Skills

Dr. Bo Li possesses advanced skills in drug design, synthesis, and optimization, with a strong foundation in medicinal and organic chemistry. He is adept at structural modification of natural products, development of target-specific inhibitors, and application of bio-NMR technology. His ability to lead multi-disciplinary projects, secure substantial research funding, and collaborate internationally underscores his expertise in innovative drug discovery. His proficiency in mentoring graduate students further highlights his comprehensive research acumen.

Awards and Honors

Dr. Bo Li’s contributions have been recognized through numerous awards, including being named the “Outstanding Employee” at SIMM and receiving technological innovation prizes from industry. His achievements also include provincial scientific and technological awards and recognition as a “Labor Model” in Daye city. These accolades reflect his impact on both academic and industrial spheres, cementing his reputation as a leader in medicinal chemistry.

Conclusion

Dr. Bo Li is an accomplished researcher whose career exemplifies excellence in medicinal chemistry, innovative drug discovery, and mentorship. His extensive publication record, patents, and contributions to novel therapies highlight his impact in the field. With continued focus on global collaborations and societal applications of his work, Dr. Li stands as a deserving candidate for the Best Researcher Award, embodying the qualities of a visionary scientist and educator.

Publication Top Notes

  1. Title: Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads
    Authors: Dong, S., Huang, H., Li, J., Li, B., Zhu, W.
    Year: 2024
  2. Title: Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma
    Authors: Li, X., Zhang, H., Dong, S., Shi, J., Zhu, W.
    Year: 2024
  3. Title: Corrigendum to “Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells”
    Authors: Feng, Q., Hu, K., Hu, H., Zhu, W., Shi, J.
    Year: 2024
  4. Title: Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors
    Authors: Wei, Y., Xiong, Y., Liao, Q., Zhu, W., Ge, G.
    Year: 2024
  5. Title: Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma
    Authors: Chen, G., Gao, X., Jia, X., Zhu, W., Shi, J.
    Year: 2024
    Citations: 6
  6. Title: Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents
    Authors: Wang, J., Zhou, C., Li, B., Zhang, H., Liu, L.
    Year: 2024
  7. Title: Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphoma
    Authors: Lai, Y., Guo, S., Tang, Q., Zhu, W., Shi, J.
    Year: 2024
  8. Title: A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
    Authors: Zhang, H., Hu, K., Lu, Y., Zhu, W., Shi, J.
    Year: 2024
  9. Title: Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo
    Authors: Dong, S., Hu, K., Shi, Y., Shi, J., Zhu, W.
    Year: 2024
    Citations: 4
  10. Title: The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway
    Authors: Wang, Y., Dong, S., Hu, K., Zhu, W., Shi, J.
    Year: 2023
    Citations: 4